Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2026 07:03 ET | Source: PMGC Holdings Inc.

PMGC Holdings Inc. [NASDAQ: ELAB] Reports 2025 Annual Results and Files Form 10-K, Company Expands Asset Base to $13.8M, a 43% Increase from 2024

PMGC Holdings Inc. [NASDAQ: ELAB] Reports 2025 Annual Results and Files Form 10-K, Company Expands Asset Base to $13.8M, a 43% Increase from 2024
March 27, 2026 16:05 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in Combination with GLP-1 Treatments

NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in
March 10, 2026 10:00 ET | Source: GLP Diet

GLP Diet Review: A Personalized App Designed to Support GLP-1 Weight Loss Journeys

GLP Diet is a personalized weight loss app supporting GLP-1 meds with tailored meals, workouts, trackers, and expert guidance for fast and lasting results.
March 10, 2026 07:30 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy

Northstrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy
February 09, 2026 06:59 ET | Source: Novo Nordisk A/S

Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy® and Ozempic®

Novo Nordisk has filed a lawsuit against telehealth firm Hims & Hers for patent infringement and putting patients’ lives at stake with knockoff drugs.
February 04, 2026 16:30 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Announces Progress Updates to Phase III Timeline for AI-Driven Drug Discovery Program with Yuva Biosciences

NorthStrive Biosciences Announces Progress Updates to Phase III Timeline for AI-Driven Drug Discovery Program with Yuva Biosciences
January 07, 2026 09:37 ET | Source: Research and Markets

GLP-1 Market Trends and Global Forecasts Report 2025: A $157.5 Bn Market by 2035 - Landscape Led by China and the U.S., Rising Partnerships, and Strong DTC-Driven Demand Push Biologics Above 65% Share

Dublin, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The "GLP-1 Market: Industry Trends and Global Forecasts, Till 2035" report has been added to ResearchAndMarkets.com's offering.The global GLP-1 market is...
January 06, 2026 10:26 ET | Source: Blaze Pizza

Blaze Pizza Turns Up the Protein with New Limited-Time “Protein-zza,” Meeting Growing Demand for GLP-1-Friendly Options

BLAZE PIZZA TURNS UP THE PROTEIN WITH NEW LIMITED-TIME “PROTEIN-ZZA,” MEETING GROWING DEMAND FOR GLP-1-FRIENDLY OPTIONS
December 23, 2025 05:02 ET | Source: Research and Markets

Semaglutide Market Outlook Report 2026-2034: Competitive Pressure From Dual/Triple Agonists and New Delivery Formats Emerges as Semaglutide Retains Share Through Care Continuity and Channel Strength

Dublin, Dec. 23, 2025 (GLOBE NEWSWIRE) -- The "Semaglutide Market Outlook 2026-2034: Market Share, and Growth Analysis" report has been added to ResearchAndMarkets.com's offering.The Semaglutide...
December 23, 2025 04:36 ET | Source: Research and Markets

Semaglutide Preparations Market - Global Forecast 2025-2030 Featuring Novo Nordisk, Gan & Lee Pharmaceuticals, Shanghai Fosun Pharmaceutical, and Luye Pharmaceutical

Dublin, Dec. 23, 2025 (GLOBE NEWSWIRE) -- The "Semaglutide Preparations Market - Global Forecast 2025-2030" has been added to ResearchAndMarkets.com's offering.As the competitive As the...